Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Lifecore Biomedical, Inc. (LFCR)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ:LFCR). The investigation concerns whether Lifecore and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

[Click here to learn more about the investigation]

On March 20, 2024, Lifecore filed its Annual Report on Form 10-K for the fiscal year ended May 28, 2023, which contained restatements of certain previously issued financial statements that corrected “errors involving the calculation of capitalized interest, valuation of inventories, and certain other adjustments related to previously divested businesses.” On this news, the price of Lifecore shares declined by $2.18 per share, or approximately 30.32%, from $7.19 per share on March 19, 2024 to close at $5.01 on March 20, 2024.

If you purchased or otherwise acquired Lifecore securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at [e-mail], or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.